Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Medical

This article was originally published in The Gray Sheet

Executive Summary

Mechanical heart valve manufacturer announces it will continue a stock repurchase program authorized by its board of directors in July ("The Gray Sheet" July 20, 1992, p. 24). Under the program, the company may repurchase up to 5% of its outstanding common stock, or approximately 2.4 mil. of the roughly 48 mil. shares outstanding. Only 265,000 shares have been repurchased to date under the program. St. Jude President and CEO Ronald Matricaria says the continuation of the repurchase program stems from the firm's belief that its stock is "significantly undervalued." He notes that "anticipation of the Clinton Administration's reform proposals, coupled with the prospect of an increasingly competitive heart valve market, has resulted in a depression of our stock price".

You may also be interested in...



Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council

The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.

EU’s New Cybersecurity Guidelines: Not Perfect, But Key Signposting For All Involved

How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?

Bio-Thera IPO Raises $241m

Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.

UsernamePublicRestriction

Register

MT000513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel